No quarterly revenue total was found in Acurx Pharmaceuticals, Inc.'s SEC filings.
Acurx Pharmaceuticals, Inc. (ACXP) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-2.25M
-0.4% vs year-ago quarter
Operating cash flow
$-1.71M
-2.4% vs year-ago quarter
Free cash flow
—
EPS
$-0.53
+72.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
5.27M
+232.5% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Staten Island, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1736243
- Former names
- Acurx Pharmaceuticals, LLC (until Jun 23, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$2.3M | -$1.7M | -$1.6M | -$2.0M | -$2.3M |
| Net income | -$2.3M | -$1.7M | -$1.6M | -$2.0M | -$2.2M |
| Diluted EPS | -$0.53 | -$0.62 | -$0.73 | -$1.23 | -$1.89 |
| Operating cash flow | -$1.7M | -$1.4M | -$1.2M | -$1.9M | -$1.7M |
| Total assets | $11.0M | $9.5M | $7.7M | $6.1M | — |
| Total liabilities | $2.8M | $2.5M | $2.4M | $2.5M | $2.6M |
| Stockholders' equity | $8.2M | $7.0M | $5.3M | $3.6M | $3.6M |
| Cash and investments | $10.7M | $9.3M | $7.6M | $5.9M | $6.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 16, 2026 | Oct 16, 2026 |
| ARS | Annual report to shareholders | Sep 1, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Apr 16, 2026 | Apr 15, 2026 |
All 245 Acurx Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.